Pfizer Inc (PFE):医療機器:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7183)
◆英語タイトル:Pfizer Inc (PFE) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7183
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:198
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, immune disorders and rare diseases, besides vaccines. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells prescription medicines through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It sells consumer healthcare products through pharmacies, retail chains, distributors and grocery and convenience stores. The company provides its products in the North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

Pfizer Inc (PFE) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Pfizer Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Pfizer Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Pfizer Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Pfizer Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 11
Pfizer Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Pfizer Inc, Medical Equipment, Deal Details 17
Venture Financing 17
RefleXion Medical Raises USD100 Million in Series C Financing 17
Neuronetics Raises USD15 Million in Series G Round of Financing 19
Cordex Systems Raises Funds in Series A Financing 21
Advanced MR Analytics Raises USD9 Million in Venture Financing 23
Molecular Stethoscope Raises USD8.2 Million in Seed Financing 24
RefleXion Medical Raises Additional USD6 Million in Series B Financing 25
RefleXion Medical Raises USD46 Million in Series B Financing 26
UE LifeSciences to Raise USD0.1 Million in Seed Financing 27
RefleXion Medical Raises US$11.6 Million In Series A Round 29
NeuMoDx Raises US$21 Million In Series B Financing 30
Nodality Raises US$15 Million In Venture Financing Round 31
Partnerships 32
Pfizer Enters into Licensing Agreement with Scripps Research Institute 32
Pfizer Enters into Licensing Agreement with Pelago Bioscience 33
Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 34
Myriad Genetics and Pfizer Enter into Agreement 35
CYTOO Enters into Research and Option Agreement with Pfizer 36
Exact Sciences and Pfizer Enter into Co-Promotion Agreement 37
Antares Pharma Enters into Development Agreement with Pfizer 38
Foundation Medicine Enters into Agreement with Pfizer 39
InSphero Enters into Agreement with Pfizer 40
Guardant Health Enters into Agreement with AstraZeneca, Merck and Pfizer 41
Molecular Stethoscope Enters into Research Agreement with Pfizer 42
Iatric Systems Enters into Agreement with Hospira 43
Pfizer Enters into Distribution Agreement Adhezion Biomedical 44
Pfizer Enters into Research Agreement with International Business Machines 45
Medivation and NanoString Technologies Enters into Partnership With Astellas Pharma 46
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 47
Merck and Pfizer Enters into Agreement with Dako 48
Pfizer Enters into Evaluation Agreement with BIRAD 49
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 50
Siemens Healthcare Enters Into Co-Development Agreement With Pfizer 51
Protagen Enters Into Biomarker Discovery Agreement With Pfizer 52
MaRS Innovation Enters Into Partnership With Pfizer 53
Dako Enters Into Agreement With Pfizer For Companion Diagnostics 54
Hospira Enters Into Distribution Agreement With Q Core Medical For Sapphire Infusion System 55
Humedica Enters Into Agreement With Pfizer 56
Stellar Pharma Enters Into Co-Marketing Agreement With Pfizer Canada For Gelfoam 57
Ventana Medical Systems Enters Into Co-Development Agreement With Pfizer 58
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 59
Equity Offering 60
Pfizer Files Registration Statement for Public Offering of Securities 60
Debt Offering 61
Pfizer Raises USD1 Billion in Public Offering of 3.2% Notes Due 2023 61
Pfizer Raises USD0.3 Billion in Public Offering of Floating Rate Notes Due 2023 63
Pfizer Raises USD0.7 Billion in Public Offering of 4.1% Notes Due 2038 65
Pfizer Raises USD1 Billion in Public Offering of 4.2% Notes Due 2048 67
Pfizer Raises USD1 Billion in Public Offering of 3% Notes Due 2021 69
Pfizer Raises USD1 Billion in Public Offering of 3.6% Notes Due 2028 71
Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047 73
Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019 75
Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027 77
Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020 79
Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022 81
Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046 83
Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019 85
Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036 87
Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021 89
Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026 91
Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 93
Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 95
Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 97
Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 99
Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 101
Asset Transactions 103
ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 103
Acquisition 105
Pfizer Acquires Hospira for USD16.1 Billion 105
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 107
Pfizer May Increase Bid to Acquire AstraZeneca 108
Premier Acquires TheraDoc from Hospira for USD108.6 Million 110
Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 111
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 113
Covidien Completes Acquisition Of superDimension, Pulmonary Device Maker, For US$300 Million 115
Pfizer Inc – Key Competitors 117
Pfizer Inc – Key Employees 118
Pfizer Inc – Locations And Subsidiaries 120
Head Office 120
Other Locations & Subsidiaries 120
Joint Venture 143
Recent Developments 144
Strategy And Business Planning 144
Jul 24, 2018: Pfizer to build $465m injectable medicines facility in US 144
Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri 145
Jun 27, 2017: Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri 146
Financial Announcements 147
Jul 31, 2018: Pfizer reports second-quarter 2018 results 147
Jul 11, 2018: Pfizer to Organize for Future Growth 152
May 01, 2018: Pfizer Reports First-Quarter 2018 Results 154
Jan 30, 2018: Pfizer Reports Fourth-Quarter And Full-Year 2017 Results 158
Oct 31, 2017: Pfizer Reports Third-Quarter 2017 Results 165
Aug 01, 2017: Pfizer Reports Second-Quarter 2017 Results 168
May 02, 2017: Pfizer Reports First-Quarter 2017 Results 172
Jan 31, 2017: Pfizer Reports Fourth-Quarter And Full-Year 2016 Results 176
Corporate Communications 181
Oct 09, 2018: Pfizer announces Executive Leadership Team 181
Oct 01, 2018: Pfizer announces CEO succession 182
Mar 05, 2018: Pfizer Names Dan R. Littman As Board Director 184
Feb 23, 2018: Pfizer Appoints Albert Bourla As Board Director 185
Nov 13, 2017: Pfizer Names Albert Bourla Chief Operating Officer 186
Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri 188
Feb 23, 2017: Ronald E. Blaylock Elected to Pfizer’s Board of Directors 189
Product News 190
May 02, 2018: CENTOGENE Highlights Solutions for Early Diagnosis of Rare Hereditary Disorders at the 2nd Annual Recent Advances in Rare Disease Conference 190
Other Significant Developments 191
Aug 23, 2018: Exact Sciences and Pfizer to co-market colorectal cancer diagnosis test 191
Jul 10, 2018: Secretary Azar Statement Regarding Pfizer’s Drug Pricing Announcement 192
Jul 10, 2018: Pfizer’s announces it will defer company’s price increases 193
Jun 06, 2018: Pfizer Opens Call for Proposals for Neuroscience Start-ups to Apply for LabCentral Residency 194
May 21, 2018: Association of Community Cancer Centers and Pfizer Offer Grant Opportunities Focused on Improving Quality of Breast Cancer Care Through Evidence-Based BRCA Genetic Testing 195
Apr 10, 2018: Pfizer Signs Lease for The Spiral at Hudson Yards in Manhattan 196
Aug 17, 2017: OpenEye Announces Pfizer To Adopt Orion Cloud Platform For Computational Chemistry 197
Appendix 198
Methodology 198
About GlobalData 198
Contact Us 198
Disclaimer 198

List of Tables
Pfizer Inc, Medical Equipment, Key Facts, 2017 2
Pfizer Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Pfizer Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Pfizer Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Pfizer Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Pfizer Inc, Deals By Market, 2012 to YTD 2018 11
Pfizer Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
RefleXion Medical Raises USD100 Million in Series C Financing 17
Neuronetics Raises USD15 Million in Series G Round of Financing 19
Cordex Systems Raises Funds in Series A Financing 21
Advanced MR Analytics Raises USD9 Million in Venture Financing 23
Molecular Stethoscope Raises USD8.2 Million in Seed Financing 24
RefleXion Medical Raises Additional USD6 Million in Series B Financing 25
RefleXion Medical Raises USD46 Million in Series B Financing 26
UE LifeSciences to Raise USD0.1 Million in Seed Financing 27
RefleXion Medical Raises US$11.6 Million In Series A Round 29
NeuMoDx Raises US$21 Million In Series B Financing 30
Nodality Raises US$15 Million In Venture Financing Round 31
Pfizer Enters into Licensing Agreement with Scripps Research Institute 32
Pfizer Enters into Licensing Agreement with Pelago Bioscience 33
Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 34
Myriad Genetics and Pfizer Enter into Agreement 35
CYTOO Enters into Research and Option Agreement with Pfizer 36
Exact Sciences and Pfizer Enter into Co-Promotion Agreement 37
Antares Pharma Enters into Development Agreement with Pfizer 38
Foundation Medicine Enters into Agreement with Pfizer 39
InSphero Enters into Agreement with Pfizer 40
Guardant Health Enters into Agreement with AstraZeneca, Merck and Pfizer 41
Molecular Stethoscope Enters into Research Agreement with Pfizer 42
Iatric Systems Enters into Agreement with Hospira 43
Pfizer Enters into Distribution Agreement Adhezion Biomedical 44
Pfizer Enters into Research Agreement with International Business Machines 45
Medivation and NanoString Technologies Enters into Partnership With Astellas Pharma 46
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 47
Merck and Pfizer Enters into Agreement with Dako 48
Pfizer Enters into Evaluation Agreement with BIRAD 49
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 50
Siemens Healthcare Enters Into Co-Development Agreement With Pfizer 51
Protagen Enters Into Biomarker Discovery Agreement With Pfizer 52
MaRS Innovation Enters Into Partnership With Pfizer 53
Dako Enters Into Agreement With Pfizer For Companion Diagnostics 54
Hospira Enters Into Distribution Agreement With Q Core Medical For Sapphire Infusion System 55
Humedica Enters Into Agreement With Pfizer 56
Stellar Pharma Enters Into Co-Marketing Agreement With Pfizer Canada For Gelfoam 57
Ventana Medical Systems Enters Into Co-Development Agreement With Pfizer 58
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 59
Pfizer Files Registration Statement for Public Offering of Securities 60
Pfizer Raises USD1 Billion in Public Offering of 3.2% Notes Due 2023 61
Pfizer Raises USD0.3 Billion in Public Offering of Floating Rate Notes Due 2023 63
Pfizer Raises USD0.7 Billion in Public Offering of 4.1% Notes Due 2038 65
Pfizer Raises USD1 Billion in Public Offering of 4.2% Notes Due 2048 67
Pfizer Raises USD1 Billion in Public Offering of 3% Notes Due 2021 69
Pfizer Raises USD1 Billion in Public Offering of 3.6% Notes Due 2028 71
Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047 73
Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019 75
Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027 77
Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020 79
Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022 81
Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046 83
Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019 85
Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036 87
Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021 89
Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026 91
Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 93
Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 95
Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 97
Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 99
Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 101
ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 103
Pfizer Acquires Hospira for USD16.1 Billion 105
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 107
Pfizer May Increase Bid to Acquire AstraZeneca 108
Premier Acquires TheraDoc from Hospira for USD108.6 Million 110
Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 111
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 113
Covidien Completes Acquisition Of superDimension, Pulmonary Device Maker, For US$300 Million 115
Pfizer Inc, Key Competitors 117
Pfizer Inc, Key Employees 118
Pfizer Inc, Subsidiaries 120
Pfizer Inc, Joint Venture 143

List of Figures
Pfizer Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Pfizer Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Pfizer Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Pfizer Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Pfizer Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Pfizer Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 9
Pfizer Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Pfizer Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 11

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Pfizer Inc (PFE):医療機器:M&Aディール及び事業提携情報(Pfizer Inc (PFE) - Medical Equipment - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆